TRAVATAN Drug Patent Profile

Which patents cover Travatan, and when can generic versions of Travatan launch?

Travatan is a drug marketed by Alcon Pharms Ltd and Sandoz and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TRAVATAN is travoprost. There are fifteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan

A generic version of TRAVATAN was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	53
Patent Applications:	4,810
Drug Prices:	Drug price information for TRAVATAN
DailyMed Link:	TRAVATAN at DailyMed

See drug prices for TRAVATAN

Recent Clinical Trials for TRAVATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN clinical trials

Paragraph IV (Patent) Challenges for TRAVATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN	Ophthalmic Solution	travoprost	0.004%	021257	1	2008-11-28

US Patents and Regulatory Information for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001		DISCN	Yes	No
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y

Expired US Patents for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001

EU/EMA Drug Approvals for TRAVATAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN

See the table below for patents covering TRAVATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	286880
Australia	6877994
Australia	690120
Australia	704670

Supplementary Protection Certificates for TRAVATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1514548	PA2014029	Lithuania		PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
1514548	CA 2014 00038	Denmark		PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
1920764	CA 2012 00030	Denmark

TRAVATAN (travoprost) market dynamics and financial trajectory: pricing, volume, exclusivity, and competitive pressure

Last updated: July 24, 2026

What are the key market dynamics for TRAVATAN (travoprost) in the US and EU?

Answer: TRAVATAN’s market is shaped by loss of patent-led premium pricing, heavy generic penetration in topical ophthalmology, and periodic demand shifts from formulation substitutions (vehicle, preservative system, and container/administration convenience) rather than new clinical differentiation.

Therapeutic context: how travoprost competes in glaucoma and ocular hypertension

• Class: Prostaglandin analog (PG).
• US therapeutic competition: Latanoprost, bimatoprost, and fixed combinations (where PG analog + beta blocker or other agents compress monotherapy share).
• EU competitive structure: Similar prostaglandin class competition plus local payer preferences and brand-to-generic tendering cycles.

Demand drivers that typically move prostaglandin analog volumes

• Formulation and preservative tolerance: Patient switching to products with different preservative systems (e.g., benzalkonium chloride vs alternatives) and different bottle/administration characteristics.
• Adherence and persistence: Once-daily regimens favor switching only when tolerability and access improve.
• Payer pressure: Substitution to lower-priced generics after exclusivity and patent expirations is the dominant financial lever.

Pricing dynamics

• Primary pattern: Brand erosion post-competition and aggressive discounting by incumbents once generic supply is established.
• Secondary pattern: Short-term repricing around NDC-specific availability and pharmacy network contracting.

How has TRAVATAN’s financial trajectory evolved since generic entry risk intensified?

Answer: TRAVATAN’s financial trajectory follows a standard ophthalmic small-molecule pattern: brand revenue peaks early, then declines as generic and authorized-generic options expand and as fixed-combination and competing PG analogs capture incremental share.

Revenue exposure mechanics for topical ophthalmics

For brand prostaglandin analogs, revenue declines typically accelerate when:

• multiple generic manufacturers launch the same strength/dosage form,
• payer formularies place the brand in higher tier positions,
• wholesalers and pharmacies reduce brand inventory due to margin compression.

What typically happens to margins

• Gross margin compresses with higher discounts and net price concessions.
• SG&A stays relatively fixed, making operating income track faster downward than revenue unless the brand remains large enough to sustain scale.

(Note: This section describes the mechanism of financial change; exact revenue and margin figures require product-level financial statements or audited sales data.)

What is the competitive landscape versus other prostaglandin analogs (latanoprost, bimatoprost) that drives TRAVATAN share?

Answer: TRAVATAN competes in a crowded class where marginal clinical differences are usually insufficient to defend share once generics and payer substitution are in place. Competitive pressure comes from both mono-therapy prostaglandins and fixed combinations.

Key competitive vectors

• Authorized generics and multi-source supply for travoprost brands after exclusivity.
• Formulation improvements offered by competitors (device comfort, preservative profile, and patient-experience claims).
• Fixed-combination uptake that reassigns treatment lines to combination products over time.

Switching behavior

• Clinically stable patients often remain on their current therapy until tolerability or insurance triggers switch.
• New starts track payer preference lists, which often prioritize lowest-cost options within the class.

When does TRAVATAN lose exclusivity, and what is the typical effect on market share?

Answer: TRAVATAN’s practical exclusivity window has largely been competed down; post-expiration, share shifts to generics through pharmacy substitution and payer tiering.

Exclusivity framework that matters for financial trajectory

• Patent expiry and generic entry drive the largest near-term share loss.
• Orange Book listing gaps reduce brand protection and accelerate generic uptake.
• Data exclusivity (if applicable to a particular filing history) is usually shorter than patent-driven protection.

Commercial impact pattern

• Months after first generic(s) launch: rapid share drop in covered markets.
• Following quarters: normalization around net-price contracting and pharmacy stocking behavior.

What generic entry risks exist for TRAVATAN, including Paragraph IV and ANDA pathways?

Answer: Generic entry risk for TRAVATAN is structural: travoprost is a small-molecule ophthalmic drug with broad generic feasibility once the brand’s key IP barriers clear.

How ANDA competition typically impacts branded travoprost

• Multiple ANDAs can reach launch quickly once core patents fall.
• Settlement agreements, if any, can delay entry to specific dates and limit early competition to one or a small number of filers.

What to watch in litigation/filing history

• Whether there are still active secondary patents (formulation, method-of-use, device/container, preservative composition, or specific dosing regimens).
• Whether courts or PTAB activity narrows claims that otherwise block design-around products.

What patents protect TRAVATAN, and how strong is the patent estate around formulations and methods?

Answer: For a mature prostaglandin analog, the most relevant protection usually clusters around secondary patents: formulation changes, preservative/system modifications, and specific dosing or use instructions. Core composition-of-matter protection is typically exhausted earlier.

Patent estate shapes design-around and launch timing

• Formulation patents can block “look-alike” products if they claim specific excipient systems or concentrations.
• Method-of-use patents can restrict indications or treatment instructions, though enforceability against generic labeling is litigation-intensive.
• Process/manufacturing patents can slow supply even after product-level patents clear.

(This section cannot be populated with specific patent numbers, assignees, or expiration dates from the prompt data provided.)

What is the Orange Book status of TRAVATAN, and which listings matter for generic launch timing?

Answer: TRAVATAN’s Orange Book relevance is typically concentrated in the remaining listed patents tied to the marketed dosage form and strength. When most listed patents expire or are no longer in force, ANDA entry tends to accelerate.

Which Orange Book fields drive business decisions

• Patent type (composition, method, formulation, or device)
• Expiration dates and whether patents are listed for the relevant strength/NDC
• Whether patents are delisted due to invalidity/settlement

(Specific Orange Book listing data is not included in the prompt, so it is not reproduced here.)

What FDA regulatory status does TRAVATAN have, and how does it affect market access?

Answer: TRAVATAN is an FDA-approved topical ophthalmic prostaglandin analog. The regulatory status affects manufacturing continuity, labeling, and interchangeability during competitive substitution.

Regulatory factors that influence commercial performance

• NDC-level continuity and supply stability
• Labeling that supports switching among equivalent prostaglandin therapies
• Any post-approval changes to formulation or container that create separate competitive SKUs

How do settlements and patent litigation historically affect TRAVATAN’s competitive timeline?

Answer: For established ophthalmics, settlements typically:

• set “carve-out” launch dates for specific ANDA filers,
• limit design around if terms cover formulation or labeling,
• result in delayed but eventual generic erosion.

What litigators and licensing teams usually look for

• Whether settlements cover multiple ANDAs or a single filer
• Whether the settlement includes non-monetary terms like exclusivity procurement or supply arrangements
• Whether “trigger” conditions exist (e.g., delisting, dismissal, or dismissal with prejudice)

(Specific TRAVATAN litigation and settlement terms are not provided in the prompt.)

Which dosing form and formulation changes create new commercial products within the TRAVATAN franchise?

Answer: Within ophthalmics, commercial dynamics often split by:

• strength,
• preservative system,
• and container/device features.

Commercial impact of product line fragmentation

• Distinct SKUs can retain marginal brand pricing longer if substitution is slower due to pharmacist workflows or payer rules.
• Once multiple SKUs are genericized, consolidated category pricing drops.

(No TRAVATAN franchise SKU history was included in the prompt.)

How does TRAVATAN compare commercially with other travoprost brands or generics by net price and market penetration?

Answer: The brand premium typically compresses after genericization. Net-price competition in pharmacies and group purchasing organizations leads to category-leading lowest-cost alternatives.

What drives penetration for generics

• Contracting by wholesalers and payers
• Pharmacy formulary tiers and switch policies
• Supply reliability and consistent NDC availability

(Exact pricing and penetration figures are not available in the prompt.)

What revenue exposure does TRAVATAN create for its sponsor, and where is downside risk concentrated?

Answer: Downside is concentrated in:

• ongoing generic substitution,
• payer formulary changes,
• and inability to sustain premium net pricing.

Risk concentration points

• NDC-level net price erosion
• Inventory de-stocking post-launch of multi-source generics
• Competitive capture by fixed combinations within glaucoma management algorithms

Key Takeaways

• TRAVATAN’s market dynamics in glaucoma are driven by generic substitution, payer tiering, and formulation and tolerability-based switching within prostaglandin analogs.
• The brand financial trajectory in mature ophthalmics typically follows a peak-then-decline pattern after patent-driven premium pricing erodes.
• Competitive pressure is primarily structural: multiple low-cost travoprost options plus class peers (latanoprost, bimatoprost) and fixed combinations that absorb incremental share.
• The commercial impact of Orange Book status and patent litigation is decisive for the timing of generic erosion and the speed of market share loss.

FAQs

1. How does payer formulary placement affect TRAVATAN net pricing after generic launches?
2. What product attributes (preservative system, bottle design) most influence patient switching within prostaglandin analogs?
3. Do fixed-combination glaucoma therapies reduce prostaglandin analog monotherapy share consistently across markets?
4. What litigation outcomes most commonly delay generic entry for ophthalmic brands like TRAVATAN?
5. How do NDC-level supply issues and pharmacy contracting patterns change branded ophthalmic revenue after multi-source competition?

References

1. US Food and Drug Administration. Drugs@FDA.
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.

DrugChatter Q&A for TRAVATAN

How much is travatan z without insurance?
Why is travatan z so expensive?
Generic name for travatan?
Why was travatan discontinued?
Travatan eye drops generic name?